Literature DB >> 32374280

From therapeutic drug monitoring to total drug monitoring and drug-omics.

Michael Vogeser1.   

Abstract

In view of the role of pharmacotherapy in medicine, on the one hand, and the powerful technical possibilities that are now available on the other hand, therapeutic drug monitoring is a surprisingly neglected area of laboratory medicine. In this viewpoint article, an "omics approach" to pharmacovigilance and drug monitoring is proposed and discussed. A realistic goal for laboratory medicine in the 21st century should indeed be to enable clinicians to check whether the right drug is present in the right patient with an appropriate blood concentration for each compound.

Entities:  

Keywords:  drug-omics; immunoassay; individualization; mass spectrometry; pharmacokinetics; therapeutic drug monitoring

Year:  2020        PMID: 32374280     DOI: 10.1515/cclm-2020-0339

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  2 in total

1.  An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum.

Authors:  Katharina Habler; Michael Vogeser; Daniel Teupser
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2022-02-07

2.  Lanthanide (Eu3+/Tb3+)-Loaded γ-Cyclodextrin Nano-Aggregates for Smart Sensing of the Anticancer Drug Irinotecan.

Authors:  Yaowei Guo; Jin Liu; Qinglin Tang; Cuicui Li; Yanying Zhang; Yao Wang; Yanxin Wang; Yupeng Bi; Christopher D Snow; Matt J Kipper; Laurence A Belfiore; Jianguo Tang
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.